Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03661866 · ClinicalTrials.gov registry record

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

A clinical trial of Atopic Dermatitis and Psoriasis, sponsored by Target PharmaSolutions.

Active
Registry status
15,000
Enrollment target
20
Study locations

NCT03661866 is a study of Atopic Dermatitis and Psoriasis that is active but no longer recruiting, run by Target PharmaSolutions. The registered enrollment target is 15,000 participants, above the 509-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (2847% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03661866, a study of Atopic Dermatitis and Psoriasis, is active but no longer recruiting, sponsored by Target PharmaSolutions.

ACTIVE NOT RECRUITING
Registry status
15,000 participants
Enrollment target
20
Study locations

Study Summary

TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

Conditions Studied

Atopic Dermatitis Psoriasis Hidradenitis Suppurativa Alopecia Areata Chronic Spontaneous Urticaria Vitiligo

Study Locations (20)

California

  • First OC Dermatology - Fountain Valley
  • Center for Dermatology Cosmetic and Laser Surgery - Fremont
  • University of California - Irvine
  • University of California - San Diego/Rady Children's Hospital - San Diego

Arkansas

  • Johnson Dermatology - Fort Smith
  • University of Arkansas for Medical Sciences - Little Rock
  • Arkansas Dermatology - Little Rock

Florida

  • Feinstein Dermatology and Cosmetic Surgery - Hollywood
  • Academic Alliance in Dermatology - Tampa
  • Integrated Dermatology of West Palm Beach - West Palm Beach

Massachusetts

  • Integrated Dermatology of Massachusetts - Quincy
  • University of Massachusetts Medical School - Worcester

Arizona

  • Clear Dermatology & Aesthetics Center/Investigative MD - Scottsdale

District of Columbia

  • George Washington University - Washington D.C.

Illinois

  • Lurie Children's Hospital/Northwestern University - Chicago

Indiana

  • Dawes Fretzin Dermatology/ Dawes Fretzin Clinical Research Group - Indianapolis

Trial Details

FieldValue
Enrollment Target 15,000 participants
Start Date 2018-12-21
Est. Completion 2050-12

Sponsor

Target PharmaSolutions

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03661866

The ClinicalTrials.gov registry entry for NCT03661866 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 15,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 509-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (2847% higher). The listed sponsor is Target PharmaSolutions, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 0 interventions.

NCT03661866 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Arkansas, Florida.

Frequently Asked Questions

What is clinical trial NCT03661866 about?

NCT03661866 is a clinical study titled "A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC". TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and com...

What is the current status of trial NCT03661866?

This trial is currently active not recruiting. The enrollment target is 15,000 participants. The study started on 2018-12-21. Estimated completion is 2050-12.

What conditions does trial NCT03661866 study?

This clinical trial studies the following conditions: Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Alopecia Areata, Chronic Spontaneous Urticaria.

Who is sponsoring clinical trial NCT03661866?

This trial is sponsored by Target PharmaSolutions, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03661866 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atopic Dermatitis

All registered trials for this condition

Psoriasis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.